Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
-$0.25 today
- Market cap
- $1.57B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
Volume 2.15M
Average 1.76M
VIR Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Vir Biotechnology, Inc.NASDAQ: VIR
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $2.81M fell 2.0% year over year, behind the +41.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.0% from the prior quarter. Over 3 fiscal years it compounded at +46.1% a year.
Context
- Depreciation & amortization amounted to 30.9% of revenue in FY2025, up 11.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.0% toward the trailing-twelve-month pace of +41.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 21.15M USD
- Year-over-year change
- +45.3%
- 4-year CAGR
- +38.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.15M | +45.3% |
| FY2024 | 2024-12-31 | 14.56M | -25.2% |
| FY2023 | 2023-12-31 | 19.45M | +186.8% |
| FY2022 | 2022-12-31 | 6.78M | +16.7% |
| FY2021 | 2021-12-31 | 5.81M | — |
Depreciation & Amortization vs competitors
How VIR compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +41.3% is the 5th highest of 10, against a peer median of +23.6%.
- Depreciation & amortization amounts to 27.8% of revenue for VIR, versus a peer median of 5.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €676.85M EUR | +122.9% | +43.9% | 25.6% | |
| LTM Sep 2026 | $257M USD | +23.6% | -14.8% | 10.2% | |
| LTM Mar 2026 | €25.21M EUR | +138.6% | +1.1% | 16.1% | |
| LTM Mar 2026 | $22.34M USD | -50.0% | -1.7% | 3.7% | |
| LTM Mar 2026 | $18.23M USD | +41.3% | +46.1% | 27.8% | |
| LTM Jun 2026 | $5.95M USD | +365.1% | -1.1% | 0.6% | |
| LTM Mar 2026 | $4.95M USD | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $1.07M USD | -21.3% | -36.6% | 0.6% | |
| LTM Mar 2026 | $416K USD | +0.0% | +17.0% | — | |
| LTM Mar 2026 | $122K USD | -6.2% | -36.3% | 0.2% | |
| Peer median (excluding VIR) | — | +23.6% | -1.1% | 5.5% | |
Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 528.58M | 515.84M | (615.06M) | (521.96M) | (437.99M) |
| Depreciation & Amortization | 5.81M | 6.78M | 19.45M | 14.56M | 21.15M |
| Deferred Income Tax | 15.19M | (15.19M) | (1.06M) | (2.95M) | 0 |
| Stock-Based Compensation | 83.78M | 102.08M | 0 | 78.46M | 49.07M |
| Change in Working Capital | (628.39M) | 665.37M | (304.59M) | (84.01M) | (22.45M) |
| Accounts Receivables | (773.08M) | 770.04M | (565K) | (6.51M) | 0 |
| Inventory | 52.82M | 0 | 0 | 0 | 0 |
| Accounts Payables | (171K) | 797K | 732K | (988K) | 5M |
| Other Working Capital | 92.04M | (105.47M) | (304.76M) | (76.51M) | (27.44M) |
| Other Non-Cash Items | (52.56M) | 388.37M | 122.48M | 69.55M | (1.57M) |
| Operating Cash Flow | (47.59M) | 1.66B | (778.79M) | (446.35M) | (391.78M) |
| Capital Expenditures | (21.82M) | (68.01M) | (21.57M) | (7.3M) | (4.83M) |
| Acquisitions (Net) | 140.81M | 0 | 100K | 3.37M | 253K |
| Purchases of Investments | (420.24M) | (1.48B) | (2.02B) | (1.24B) | (886.33M) |
| Sales of Investments | 301.24M | 351.51M | 2.2B | 1.74B | 1.2B |
| Other Investing Activities | (140.81M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (140.81M) | (1.19B) | 164.73M | 499.37M | 310.37M |
| Debt Repayment | (259K) | (260K) | (287K) | (165K) | (361K) |
| Common Stock Issued | 85.21M | 28.46M | 7.77M | 4.55M | 4.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.38M | 6.56M | (100K) | 0 | 0 |
| Financing Cash Flow | 100.33M | 34.76M | 7.38M | 4.39M | 3.79M |
| Effect of Forex Changes | 0 | 0 | 208K | 0 | 0 |
| Net Change in Cash | (88.07M) | 504.55M | (606.47M) | 57.4M | (77.63M) |
| Free Cash Flow | (69.41M) | 1.6B | (800.36M) | (453.65M) | (396.61M) |
Vir Biotechnology, Inc.
NASDAQ:VIR
Intrinsic Alpha fair value
Locked
Current Price
$9.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.